SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, CPE, BRBS

NEW YORK, Jan. 9, 2024

Gracell Biotechnologies Inc. (NASDAQ: GRCL)'s sale to AstraZeneca. Under the terms of the proposed transaction, AstraZeneca will acquire Gracell for $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ADS of Gracell) payable upon achievement of a specified regulatory milestone. If you are a Gracell shareholder, click here to learn more about your rights and options.

RayzeBio, Inc. (NASDAQ: RYZB)'s sale to Bristol-Myers Squibb Company for $62.50 per share in cash. If you are a RayzeBio shareholder, click here to learn more about your rights and options.  

Callon Petroleum Company (NYSE: CPE)'s sale to APA Corporation for 1.0425 shares of APA common stock for each share of Callon common stock. Upon closing, Callon shareholders are expected to own approximately 19% of the combined company. If you are a Callon shareholder, click here to learn more about your rights and options.  

Blue Ridge Bankshares, Inc. (NYSE: BRBS)'s definitive securities purchase agreements with BRB Financial Group, Inc. to issue gross proceeds of $150,000,000 of Blue Ridge's common stock. If you are a Blue Ridge shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.